InnoSer facilitates scientific biomedical research in a professional, efficient and responsible manner
There needs to be a focus on accelerating biomedical research in Europe and promoting Europe as a centre of medical research innovation. Improved coordination and consolidation of excellent research across Europe and scientific input in biomedical research initiatives from the outset are vital to tackle the significant societal challenges in this domain. This means that science within Europe should choose to join forces by connecting networks, by standardization, by interoperability, by reducing costs, and by working transparently. Only then, Europe will be able to track the competition with America and Asia.
InnoSer is an important, relatively new player on the market that facilitates the European scientific biomedical research in an innovative, efficient, professional and responsible manner. InnoSer offers laboratory animal services in the field of genetically modified (genetically altered, GA) in vivo and in vitro models for biomedical research.
InnoSer’s service portfolio includes: preclinical services, invivo & invitro pharmacology, colony management, sanitation, cryopreservation and rederivation as well as generation and pathological analysis of Genetically Engineered Mouse Models. The services are local, well defined and under standardized conditions. InnoSer focuses entirely on professional support of researchers by field experts, keeping tight schedules and providing flexibility under highly attractive terms!
InnoSer’s activities are based on the 3 R’s concept, Replacement, Reduction and Refinement. Corporate Societal Responsibility, or CSR, is the guiding principle in the company culture. InnoSer combines experience in commercial activities of a large state-of-the-art service facility for GA research models with expertise in the field of biomedical research. InnoSer is fully equipped to provide quality services and facilitates medical research while optimal conditions and animal welfare are part of the corporate culture.
InnoSer offers laboratory services at competitive prices, made possible by both collaboration with partners and economy-of-scale. The business concept is based on the principle that the (intellectual) property of GA animal models and ownership remains with the scientist or scientific institute.
InnoSer, founded in 2011, meets the growing demands for professional expertise and infrastructure for scientific research institutes and commercial companies in European countries. InnoSer believes that collaboration between partners will enhance the efficient use of scarce research service facilities and simultaneously optimize the usage of highly technical resources from both public and private organizations.
Genetically modified mouse lines (GM-mice) are key to basic life sciences to identify roles of genes and gene products in development, physiology and disease, and to innovative research in Biomedical sciences. The creation and complex breeding of GM-mice is done by research institutions (mostly public organizations) but there are ethical and managerial challenges for more efficiency in order to avoid the production of unnecessary surplus animals and expansion of facilities. Other concerns are preservation of the genotypes that are key to institutional programs, and animal health status.
By virtue of more efficient mouse colony maintenance (at a lesser integrated cost) and eliminating long delays for importing non-SPF mouse lines into an SPF-facility, life sciences and biomedical research in Belgium will be intrinsically strengthened which will lead to more economic spending of public funds for research. It will enhance competitiveness of public and private research, and lead to faster translation of the outcomes to applications that will benefit health and quality of life, with the societal benefits that depend on such developments.
This solution addresses effectively the societal concern about the breeding surplus animals that are quite inevitable in small scale breeding. Not only will the breeding be rationalized, also the sharing of organs and tissues for research will be promoted which will not only benefit integrated phenotyping but will also allow prospective users of a model to do some preliminary testing to investigate whether the model of interest fits their demands. This will promote optimal use of animals raised, thus saving on the use of live animals and their transport which is stressful. Similarly, organs and tissues can be prepared for pathological evaluation according to internationally standardized protocols.
Early cataloging will promote the broad phenotyping of novel models and the sharing of animals between institutions, and, similarly, the sharing of high-end research facilities.
InnoSer strongly supports the 3R-principles to animal testing. The facility will promote Reduction and Refinement of animal use by enhancing the efficiency of animal use and the development and implementation of best practices, thereby reducing the numbers of surplus animals bred for a project. The sharing of organs and tissues will provide a rich resource of biomaterials to be used in in vitro research, thus promoting the Replacement of experimentation with live animals.
The creation and use of GM-mice is key to innovative biomedicine and life sciences research and highly relevant to the European Life Sciences. There are, however, concerns about the efficiency of the management and the characterization of such mouse models and opportunities missed by lack of harmonization.
InnoSer’s core facility will support biomedical research by:
- An infrastructure for the –investigator driven- centralized breeding, maintenance, cryopreservation, generation, distribution and characterization of GM-mice and facilitated access to high end technologies available through the multicenter network (generation of new mouse models, pathology, bio-imaging, behavioural and other phenotyping platforms and cryopreservation and re-derivation techniques)
- Development of well-defined animal models (nature and nurture) for specific fields of biomedical research (e.g. inflammatory, cardiovascular, (developmental) neurobiological, life style and healthy ageing), optimization and harmonization.
- Preclinical services, offering flexibility and tailored services in facilitating in-vivo / in-vitro pharmacology under highly attractive conditions. We can also offer experimental rooms and execute studies according your needs.
- Contribution to 3R-alternatives and enhancement of mouse models for translational research. Learning and training environment on high end research technologies.
- Enhanced competitiveness of European academia and innovative industry. The InnoSer facility will become showcase of advanced genetically modified animal breeding and phenotyping technology. Costs for breeding and maintenance will be reduced due to economy-of-scale and easier exchange of animals between scientific partners.
- Central animal management database. This offers the unique opportunity to include all mice models in one database accessable for the scientific community, upon mutual agreement only.
- Making in the consortia generated research models (mice, rats) available for the research community in a distribution agreement. Innoser will, on request of the owner of the model, make the models available through the website and take care of orders, administration, distribution and invoicing. InnoSer will act as a facilitator on behalf of the owners (academic partners Stability).
- InnoSer will be able to provide cutting–edge techniques and expertise in the molecular and morphological analysis of genetically modified rodents by a team of board-certified veterinary pathologists with graduate and postgraduate training in genetics as well as cellular and molecular biology.
Strategic significance for collaborative research.
Exchange of GM-rodent models is essential for the optimal use of science infrastructure and for the advancement of science. GM rodent models (mice) have provided for animal models of human disease, have clarified the role of genes and provided mechanistic insights in physiology and disease, and provide animals that better model for humans. They have changed the face of biomedical research in, for example, cancer research where now the molecular basis of disease is unravelled resulting in better diagnostic and treatment approaches.
The InnoSer core facility is complementary to existing repositories and will enhance the competitiveness of academia and commercial partners by providing more easy access to the collections of repositories by import services and reviving lines from frozen stock. This needs to be done only once for a breeding colony available to different users. The advantages of sharing a breeding facility, import/export services and GEMM services, as well as phenotyping for a wide range of traits (often highly specialized) are only achieved at the largest institutions where many scientific disciplines create and use mouse models for a great variety of models.